Agomab Therapeutics NV has announced an $89 million (€82.1 million) Series D financing round, featuring contributions from new investors Sanofi and Invus, alongside support from existing investors.
Agomab Therapeutics plans to use the $89 million from its Series D financing to advance clinical development of its lead candidate, AGMB-129, an oral small molecule inhibitor targeting ALK5 (TGFβ1R) for fibrostenosing Crohn’s disease (FSCD). Interim data from the Phase 2a STENOVA trial is expected in early 2025. The funds will also support the clinical development of AGMB-447, an inhaled small molecule inhibitor for idiopathic pulmonary fibrosis (IPF), currently in Phase 1 trials, and the initial development of AGMB-101, a MET agonistic antibody for liver cirrhosis.
“We are excited to welcome Sanofi and Invus to our investor group, alongside the ongoing support from our existing shareholders,” said Tim Knotnerus, CEO of Agomab Therapeutics. “This financing will enhance our options and accelerate the development of our innovative therapies.”
About Agomab
Agomab is dedicated to modifying diseases by targeting fibrosis and regeneration in conditions like fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. The company focuses on biologically validated pathways, leveraging specialized small molecules and high-affinity antibodies. With a robust clinical pipeline, comprehensive R&D capabilities, and a strong investor base, Agomab aims to become a leader in biopharma.
